Hyperkalemia medical therapy

Jump to navigation Jump to search
<figure-inline><figure-inline><figure-inline><figure-inline><figure-inline><figure-inline><figure-inline><figure-inline><figure-inline><figure-inline></figure-inline></figure-inline></figure-inline></figure-inline></figure-inline></figure-inline></figure-inline></figure-inline></figure-inline></figure-inline>

Resident
Survival
Guide

Hyperkalemia Microchapters

Home

Patient information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Hyperkalemia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural history, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Hyperkalemia medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Hyperkalemia medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Hyperkalemia medical therapy

CDC on Hyperkalemia medical therapy

Hyperkalemia medical therapy in the news

Blogs on Hyperkalemia medical therapy

Directions to Hospitals Treating Hyperkalemia

Risk calculators and risk factors for Hyperkalemia medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-In-Chief: Priyamvada Singh, M.B.B.S. [2] Jogeet Singh Sekhon

Overview

When arrhythmias occur, or when potassium levels exceed 6.5 mmol/l, emergency lowering of potassium levels is mandated. Several agents are used to lower potassium levels. Choice depends on the degree and cause of the hyperkalemia, and other aspects of the patient's condition.

Medical Therapy

  • Calcium supplementation (calcium gluconate 10%), preferably through a central venous catheter as the calcium may cause phlebitis) does not lower potassium but decreases myocardial excitability, protecting against life threatening arrhythmias [1]
  • Magnesium sulfate is used to stabilize cardiac membrane in cases of hyperkalemia due to digoxin toxicity and hyperkalemia in hypercalcemic states.
  • Insulin will lead to a shift of potassium ions into cells, secondary to increased activity of the sodium-potassium ATPase.
  • Bicarbonate therapy is effective in cases of metabolic acidosis. The bicarbonate ion will stimulate an exchange of cellular H+ for Na+, thus leading to stimulation of the sodium-potassium ATPase.
  • Salbutamol (albuterol, Ventolin®) is a β2-selective catecholamine that his drug promotes movement of K+ into cells, lowering the blood levels.
  • Polystyrene sulfonate (calcium resonium, kayexalate) is a binding resin that binds K within the intestine and removes it from the body by defecation.nemti. This medication may cause diarrhea and takes a lot of time to lower the potassium levels.
  • Refractory or severe cases may need dialysis to remove the potassium from the circulation.
  • Preventing recurrence of hyperkalemia typically involves reduction of dietary potassium, removal of an offending medication, and/or the addition of a diuretic (such as furosemide (Lasix®) or hydrochlorothiazide).
  • Patiromer anion is a potassium binding ion cation exchange polymer that increases the gastrointestinal excretion of potassium. Patiromer should not be used as an emergency treatment for life-threatening hyperkalemia because of its delayed onset of action.

Practical approach to treat hyperkalemia

  • Look for ECG changes
  • Look for reversible causes of hyperkalemia such as supplemental potassium

1.Cardiac Membrane stabilization

2.Increase potassium shift from extracellular to intracellular spaces

  • IV insulin with 2.5-5 ml/kg/h 20% dextrose (0.5-1 g/kg/h) with insulin 0.2 units for every gram of glucose administered.[2][3]
Salbutamol (ten drops of standard sabutamol inhalation solution contain 2.5 mg) iv: 4-5 μg/kg in 15 ml of 5% dextrose/water, short infusion over 15 min
Nebulized: 2.5 mg if <25 kg and 5 mg if >25 kg
  • Alternate regime-Bicarbonate(Sodium bicarbonate 8.4%) 1-2 mmol/kg over 30-60 min or calculated on base-deficit in cases of acidosis. [4]

3.Increase potassium excretion [5]

  • Furosemide can be given Intravenously or orally, in dose of 1-2mg/kg.
  • Polystyrene sulfonate (Calcium Resonium, Kayexalate) given P.O or P.r given in the dose of 1g\kg.
  • Renal replacement therapy-It is the most effective manner to remove potassium.Haemodialysis is usually done in patients with severe hyperkalemia in chronic renal failure patients.[6]

Contraindicated medications

Hyperkalemia is considered a relative contraindication to the use of the following medications:


Hyperkalemia (Serum potassium >5.5 mEq/L) is considered an absolute contraindication to the use of the following medications:

References

  1. Ingelfinger JR (2015). "A new era for the treatment of hyperkalemia?". N Engl J Med. 372 (3): 275–7. doi:10.1056/NEJMe1414112. PMID 25415806.
  2. Alvestrand A, Wahren J, Smith D, DeFronzo RA (1984). "Insulin-mediated potassium uptake is normal in uremic and healthy subjects". Am J Physiol. 246 (2 Pt 1): E174–80. doi:10.1152/ajpendo.1984.246.2.E174. PMID 6364842.
  3. Blumberg A, Weidmann P, Shaw S, Gnädinger M (1988). "Effect of various therapeutic approaches on plasma potassium and major regulating factors in terminal renal failure". Am J Med. 85 (4): 507–12. PMID 3052050.
  4. Blumberg A, Weidmann P, Ferrari P (1992). "Effect of prolonged bicarbonate administration on plasma potassium in terminal renal failure". Kidney Int. 41 (2): 369–74. PMID 1552710.
  5. Allon M (1995). "Hyperkalemia in end-stage renal disease: mechanisms and management". J Am Soc Nephrol. 6 (4): 1134–42. PMID 8589279.
  6. Allon M, Shanklin N (1995). "Effect of albuterol treatment on subsequent dialytic potassium removal". Am J Kidney Dis. 26 (4): 607–13. PMID 7573015.